This article has been cited by
1Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis
Sameer S. Udhane,Bernhard Dick,Qingzhong Hu,Rolf W. Hartmann,Amit V. Pandey
Biochemical and Biophysical Research Communications.2016;477(4)1005
[DOI]
2Electrolyte Disorders Induced by Antineoplastic Drugs
Ignazio Verzicco,Giuseppe Regolisti,Federico Quaini,Pietro Bocchi,Irene Brusasco,Massimiliano Ferrari,Giovanni Passeri,Valentina Cannone,Pietro Coghi,Enrico Fiaccadori,Alessandro Vignali,Riccardo Volpi,Aderville Cabassi
Frontiers in Oncology.2020;10(4)1005
[DOI]
3Solubility Measurements at 296 and 310 K and Physicochemical Characterization of Abiraterone and Abiraterone Acetate
Tamás Solymosi,Ferenc Tóth,János Orosz,Orsolya Basa-Dénes,Réka Angi,Tamás Jordán,Zsolt Ötvös,Hristos Glavinas
Journal of Chemical & Engineering Data.2018;10(4)1005
[DOI]
4Solubility Measurements at 296 and 310 K and Physicochemical Characterization of Abiraterone and Abiraterone Acetate
Nerethika Ravichandiran,Muneesh Kumar Barman,Sai Tejaswi Lavuri,Manjita Srivastava,Shalini Sakthivel,Meenakshi Singh,Kailash Chand,Subash C. Sonkar,Prudhvilal Bhukya
Journal of Chemical & Engineering Data.2021;10(4)433
[DOI]
5Hormone resistance and neuroendocrine differentiation due to accumulation of genetic lesions during clonal evolution of prostate cancer
D. S. Mikhaylenko,G. D. Efremov,A. V. Sivkov,D. V. Zaletaev
Molecular Biology.2016;50(1)28
[DOI]
6Determining direct binders of the Androgen Receptor using a high-throughput Cellular Thermal Shift Assay
Joseph Shaw,Mathew Leveridge,Charlotta Norling,Jakob Karén,Daniel Martinez Molina,Daniel O’Neill,James E. Dowling,Paul Davey,Suzanna Cowan,Michael Dabrowski,Martin Main,Davide Gianni
Scientific Reports.2018;8(1)28
[DOI]
7First results of the double-blind randomized placebo-controlled multicenter clinical trial of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN)
Mikhail Paltsev,Vsevolod Kiselev,Vadim Drukh,Ekaterina Muyzhnek,Igor Kuznetsov,Evgeniya Andrianova,Pavel Baranovskiy
EPMA Journal.2016;7(1)28
[DOI]
8First results of the double-blind randomized placebo-controlled multicenter clinical trial of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN)
Jerome F. Strauss,Garret A. FitzGerald
EPMA Journal.2019;7(1)75
[DOI]
9First results of the double-blind randomized placebo-controlled multicenter clinical trial of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN)
André Mansinho,Daniela Macedo,Isabel Fernandes,Luís Costa
EPMA Journal.2018;1126(1)117
[DOI]
10Abiraterone and D4, 3-keto Abiraterone binding to CYP17A1, a structural comparison study by molecular dynamic simulation
Havva Mehralitabar,A.S. Ghasemi,Jahed Gholizadeh
Steroids.2021;167(1)108799
[DOI]
11The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature
Ian M. Bird,David H. Abbott
The Journal of Steroid Biochemistry and Molecular Biology.2016;163(1)136
[DOI]
12One-Year, Open-Label Extension Study on the Safety and Efficacy of Abiraterone Acetate Fine Particle Formulation in Patients With Metastatic Castration-Resistant Prostate Cancer
Jillian Chapas-Reed,Cy Stein,Nicholas Squittieri,Raoul Concepcion
Clinical Medicine Insights: Urology.2020;13(1)117956112091012
[DOI]
13Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review
Archana Anantharaman,Terence W. Friedlander
Urologic Oncology: Seminars and Original Investigations.2016;34(8)356
[DOI]
14Increased Expression of AKT3 in Neuroendocrine Differentiated Prostate Cancer Cells Alters the Response Towards Anti-Androgen Treatment
Marc Wiesehöfer,Elena Dilara Czyrnik,Martin Spahn,Saskia Ting,Henning Reis,Jaroslaw Thomas Dankert,Gunther Wennemuth
Cancers.2021;13(3)578
[DOI]
15Increased Expression of AKT3 in Neuroendocrine Differentiated Prostate Cancer Cells Alters the Response Towards Anti-Androgen Treatment
Travis Van der Steen,Lucy J. Schmidt,Donald J. Tindall
Cancers.2017;13(3)967
[DOI]
16Human cytochrome P450 enzymes 5–51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition – toxic effects and benefits
Slobodan P. Rendic,F. Peter Guengerich
Drug Metabolism Reviews.2018;50(3)256
[DOI]
17Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibiting cytochrome P450 inhibition: a patent evaluation WO2015048311 (A1)
Richard L Schroeder,Phan Tram,Jiawang Liu,Maryam Foroozesh,Jayalakshmi Sridhar
Expert Opinion on Therapeutic Patents.2016;26(1)139
[DOI]
18Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA)
Yogita Patil,Hilary Shmeeda,Yasmine Amitay,Patricia Ohana,Saran Kumar,Alberto Gabizon
Nanomedicine: Nanotechnology, Biology and Medicine.2018;14(4)1407
[DOI]
19Investigational luteinizing hormone releasing hormone (LHRH) agonists and other hormonal agents in early stage clinical trials for prostate cancer
Nirmish Singla,Rashed A. Ghandour,Ganesh V. Raj
Expert Opinion on Investigational Drugs.2019;28(3)249
[DOI]
20Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (Review)
BJÖRN GEORGI,NINA KORZENIEWSKI,BORIS HADASCHIK,CARSTEN GRÜLLICH,WILFRIED ROTH,HOLGER SÜLTMANN,SASCHA PAHERNIK,MARKUS HOHENFELLNER,STEFAN DUENSING
International Journal of Oncology.2014;45(4)1337
[DOI]
21Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (Review)
Travis Van der Steen,Lucy J. Schmidt,Donald J. Tindall
International Journal of Oncology.2015;45(4)1
[DOI]
22Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics
Charles F. Polotti,Christopher J. Kim,Nadiya Chuchvara,Alyssa B. Polotti,Eric A. Singer,Sammy Elsamra
Expert Opinion on Drug Metabolism & Toxicology.2017;13(12)1265
[DOI]
23Tissue engineered scaffolds as 3D models for prostate cancer metastasis to bone
Simrit Safarulla,Pritisha S. Khillar,Sudarshan Kini,Amit Kumar Jaiswal
Materials Today Communications.2021;28(12)102641
[DOI]
24Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer
Christopher Sejong Han,Rutveej Patel,Isaac Yi Kim
Expert Opinion on Drug Metabolism & Toxicology.2015;11(6)967
[DOI]
25Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group
Joe M. O'Sullivan,Joan Carles,Richard Cathomas,Alfonso Gomez-Iturriaga,Daniel Heinrich,Gero Kramer,Piet Ost,Inge van Oort,Bertrand Tombal
European Urology Oncology.2020;3(4)455
[DOI]
26CYP17 inhibitors in prostate cancer: latest evidence and clinical potential
Anitha B. Alex,Sumanta K. Pal,Neeraj Agarwal
Therapeutic Advances in Medical Oncology.2016;8(4)267
[DOI]
27Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
Matthew Smith,Chris Parker,Fred Saad,Kurt Miller,Bertrand Tombal,Quan Sing Ng,Martin Boegemann,Vsevolod Matveev,Josep Maria Piulats,Luis Eduardo Zucca,Oleg Karyakin,Go Kimura,Nobuaki Matsubara,William Carlos Nahas,Franco Nolč,Eli Rosenbaum,Axel Heidenreich,Yoshiyuki Kakehi,Amily Zhang,Heiko Krissel,Michael Teufel,Junwu Shen,Volker Wagner,Celestia Higano
The Lancet Oncology.2019;20(3)408
[DOI]
28The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells
Lingling Fan,Guihong Peng,Arif Hussain,Ladan Fazli,Emma Guns,Martin Gleave,Jianfei Qi
Journal of Biological Chemistry.2015;290(34)20865
[DOI]
29The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells
Carmen Abbe,Bradley D. Anawalt,Stephanie T. Page
Journal of Biological Chemistry.2021;290(34)439
[DOI]
Feedback

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal